These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 27448975

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein.
    Amoury M, Mladenov R, Nachreiner T, Pham AT, Hristodorov D, Di Fiore S, Helfrich W, Pardo A, Fey G, Schwenkert M, Thepen T, Kiessling F, Hussain AF, Fischer R, Kolberg K, Barth S.
    Int J Cancer; 2016 Aug 15; 139(4):916-27. PubMed ID: 27037627
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. CSPG4 as a target for the specific killing of triple-negative breast cancer cells by a recombinant SNAP-tag-based antibody-auristatin F drug conjugate.
    Mungra N, Biteghe FAN, Malindi Z, Huysamen AM, Karaan M, Hardcastle NS, Bunjun R, Chetty S, Naran K, Lang D, Richter W, Hunter R, Barth S.
    J Cancer Res Clin Oncol; 2023 Oct 15; 149(13):12203-12225. PubMed ID: 37432459
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. ABCG2 transporter inhibitor restores the sensitivity of triple negative breast cancer cells to aminolevulinic acid-mediated photodynamic therapy.
    Palasuberniam P, Yang X, Kraus D, Jones P, Myers KA, Chen B.
    Sci Rep; 2015 Aug 18; 5():13298. PubMed ID: 26282350
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Cytotoxicity of Selenium Immunoconjugates against Triple Negative Breast Cancer Cells.
    Khandelwal S, Boylan M, Spallholz JE, Gollahon L.
    Int J Mol Sci; 2018 Oct 26; 19(11):. PubMed ID: 30373175
    [Abstract] [Full Text] [Related]

  • 13. Fine Tuning Antibody Conjugation Methods using SNAP-tag Technology.
    Chouman K, Woitok M, Mladenov R, Kessler C, Weinhold E, Hanz G, Fischer R, Meinhold-Heerlein I, Bleilevens A, Gresch G, Haugg AM, Zeppernick F, Bauerschlag D, Maass N, Stickeler E, Kolberg K, Hussain AF.
    Anticancer Agents Med Chem; 2017 Oct 26; 17(10):1434-1440. PubMed ID: 28270070
    [Abstract] [Full Text] [Related]

  • 14. Perspectives on Epidermal Growth Factor Receptor Regulation in Triple-Negative Breast Cancer: Ligand-Mediated Mechanisms of Receptor Regulation and Potential for Clinical Targeting.
    Williams CB, Soloff AC, Ethier SP, Yeh ES.
    Adv Cancer Res; 2015 Oct 26; 127():253-81. PubMed ID: 26093903
    [Abstract] [Full Text] [Related]

  • 15. The effect of subcellular localization on the efficiency of EGFR-targeted VHH photosensitizer conjugates.
    van Lith SAM, van den Brand D, Wallbrecher R, Wübbeke L, van Duijnhoven SMJ, Mäkinen PI, Hoogstad-van Evert JS, Massuger L, Ylä-Herttuala S, Brock R, Leenders WPJ.
    Eur J Pharm Biopharm; 2018 Mar 26; 124():63-72. PubMed ID: 29274374
    [Abstract] [Full Text] [Related]

  • 16. CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer.
    Wang X, Osada T, Wang Y, Yu L, Sakakura K, Katayama A, McCarthy JB, Brufsky A, Chivukula M, Khoury T, Hsu DS, Barry WT, Lyerly HK, Clay TM, Ferrone S.
    J Natl Cancer Inst; 2010 Oct 06; 102(19):1496-512. PubMed ID: 20852124
    [Abstract] [Full Text] [Related]

  • 17. The efficient elimination of solid tumor cells by EGFR-specific and HER2-specific scFv-SNAP fusion proteins conjugated to benzylguanine-modified auristatin F.
    Woitok M, Klose D, Niesen J, Richter W, Abbas M, Stein C, Fendel R, Bialon M, Püttmann C, Fischer R, Barth S, Kolberg K.
    Cancer Lett; 2016 Oct 28; 381(2):323-30. PubMed ID: 27502168
    [Abstract] [Full Text] [Related]

  • 18. Indocyanine green loaded liposome nanocarriers for photodynamic therapy using human triple negative breast cancer cells.
    Shemesh CS, Hardy CW, Yu DS, Fernandez B, Zhang H.
    Photodiagnosis Photodyn Ther; 2014 Jun 28; 11(2):193-203. PubMed ID: 24657627
    [Abstract] [Full Text] [Related]

  • 19. Optimization of a nanomedicine-based silicon phthalocyanine 4 photodynamic therapy (Pc 4-PDT) strategy for targeted treatment of EGFR-overexpressing cancers.
    Master AM, Livingston M, Oleinick NL, Sen Gupta A.
    Mol Pharm; 2012 Aug 06; 9(8):2331-8. PubMed ID: 22775587
    [Abstract] [Full Text] [Related]

  • 20. MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer.
    Kim YJ, Choi JS, Seo J, Song JY, Lee SE, Kwon MJ, Kwon MJ, Kundu J, Jung K, Oh E, Shin YK, Choi YL.
    Int J Cancer; 2014 May 15; 134(10):2424-36. PubMed ID: 24615768
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.